NEWS

Categories
Uncategorized

COMPLETION OF MEDICAL DEVICE SINGLE AUDIT PROGRAM (MDSAP)

Categories
Uncategorized

IMAGING INNOVATIONS WEBINAR

Categories
Uncategorized

AIQ SOLUTIONS PRES. & CEO ERIC HORLER WILL BE PRESENTING AT PMWC SILICON VALLEY

Technical Advancements in Clinical Learning- What’s New in 2021‍ Revolutionizing Precision Medicine One Lesion at a Time

Categories
Uncategorized

JOIN AMY J. WEISMAN PHD FROM AIQ SOLUTIONS PRESENTING ON SUNDAY, JUNE 12 AT 12:30 PM PST.

Automated Evaluation of Disease on 68Ga-DOTATATE PET/CT Images for Long-term Lesion Tracking on 177Lu-DOTATATE Therapy

Categories
Uncategorized

AIQ SOLUTIONS MENTION IN PRESS RELEASE: LUCEM HEALTH™ ANNOUNCES INNOVATION COLLABORATIVE TO BRING AI/ML TO THE FRONT LINES OF HEALTHCARE

RALEIGH, N.C., June 9, 2022 /PRNewswire/ — Lucem Health™ today launched the Lucem Health Innovation Collaborative, a partner program designed to move clinical AI/ML innovation to the front lines of healthcare. The Collaborative will help digital health innovators create, deploy, and commercialize transformational solutions powered by artificial intelligence and machine learning models.

Categories
Uncategorized

AIQ SOLUTIONS PRESIDENT & CEO ERIC HORLER AT BIO INTERNATIONAL CONVENTION 2022

“Imaging biomarkers to better evaluate and predict treatment response for complex diseases.” Company Presentation Theater 2 Wednesday, June 15, 2022 4:00 pm- 4:15 pm ( PDT)

Categories
Uncategorized

AIQ SOLUTIONS AT ASCO ANNUAL MEETING 2022 IN CHICAGO!

Find out more about AIQ Solutions technologies at kiosk IH22!

Categories
Uncategorized

AIQ SOLUTIONS AWARDED $2M PHASE II NIH SBIR GRANT TO ADVANCE DEVELOPMENT AND COMMERCIALIZATION OF A BIOMARKER TECHNOLOGY THAT PREDICTS CANCER IMMUNOTHERAPY RESPONSE

AIQ Solutions has been awarded a $2,000,000 Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to develop and commercialize novel technology for analysis and prediction of treatment response in patients with metastatic cancer treated with immunotherapy.

Categories
Uncategorized

AIQ SOLUTIONS AT 2022 AACR : NEW ORLEANS APRIL 8-13

Stop by our booth #923

Categories
Uncategorized

AIQ SOLUTIONS WILL BE ATTENDING IN-PERSON IO360 2022

Immuno-Oncology 360 2022 March 16-18, 2022 New York Marriott Brooklyn Bridge

Australian Privacy Policy AIQ's software has been cleared for clinical use under 510(k) K173444. For details, including the applicable Indications for Use, see: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K173444